prikaz prve stranice dokumenta Fibrilacija atrija i moždani udar
  Download
PDF 450.07 KB
master's thesis
Fibrilacija atrija i moždani udar
Zagreb: University of Zagreb, School of Medicine, 2017. urn:nbn:hr:105:571700
Ljaljić, Andrea
University of Zagreb
School of Medicine
Department of Neurology

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Ljaljić, A. (2017). Fibrilacija atrija i moždani udar (Master's thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:571700

Ljaljić, Andrea. "Fibrilacija atrija i moždani udar." Master's thesis, University of Zagreb, School of Medicine, 2017. https://urn.nsk.hr/urn:nbn:hr:105:571700

Ljaljić, Andrea. "Fibrilacija atrija i moždani udar." Master's thesis, University of Zagreb, School of Medicine, 2017. https://urn.nsk.hr/urn:nbn:hr:105:571700

Ljaljić, A. (2017). 'Fibrilacija atrija i moždani udar', Master's thesis, University of Zagreb, School of Medicine, accessed 23 December 2024, https://urn.nsk.hr/urn:nbn:hr:105:571700

Ljaljić A. Fibrilacija atrija i moždani udar [Master's thesis]. Zagreb: University of Zagreb, School of Medicine; 2017 [cited 2024 December 23] Available at: https://urn.nsk.hr/urn:nbn:hr:105:571700

A. Ljaljić, "Fibrilacija atrija i moždani udar", Master's thesis, University of Zagreb, School of Medicine, Zagreb, 2017. Available at: https://urn.nsk.hr/urn:nbn:hr:105:571700

Metadata
TitleFibrilacija atrija i moždani udar
Title (english)Atrial fibrillation and stroke
AuthorAndrea Ljaljić
MentorBranko Malojčić (mentor)
Committee memberZdravka Poljaković (predsjednik povjerenstva)
Committee memberMario Habek (član povjerenstva)
Committee memberBranko Malojčić (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
(Department of Neurology)
Zagreb
Defense date and country2017-07-14, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Neurology
Abstract
Fibrilacija atrija (FA) je danas najčešća srčana aritmija u općoj populaciji. Može se javiti u svakoj životnoj dobi, no njena pojavnost ipak raste u starijoj populaciji. FA značajno utječe na smrtnost i kvalitetu života. Liječenje FA može se podijeliti na kontrolu ritma i frekvencije te na prevenciju tromboembolije i smanjenje rizika za moždani udar (MU). MU podrazumijeva naglo nastale žarišne ispade neuroloških funkcija koji su posljedica poremećaja protoka kroz krvne žile mozga (uglavnom ishemije), a traju li takvi ispadi kraće od jednog sata, nazivamo ih tranzitornim ishemijskim napadajima (TIA). Smatra se da FA oko pet puta povećava rizik za MU, a kada nastupi takav MU ima veću vjeorajtnost trajnog i težeg hendikepa u odnosu na MU drugih etiologija. U procjeni rizika za razvoj MU kod pacijenata sa FA koriste se pristupi temeljeni na procjeni intenziteta rizičnih čimbenika putem CHADS2 i CHA2DS2-VASc izračuna, a s obzirom na dobiveni rezultat propisuje se specifična antitrombotska terapija. Primjenjuje se antikoagulantna terapija (varfarin), antiagregacijska (acetilsalicilna kiselina - ASK) i u novije vrijeme, novi oralni antikoagulansi (NOAK), koji uz dokazanu, usporedivu ili superiornu kliničku učinkovitost imaju manje interakcija i nuspojava od dosadašnje terapije.
Abstract (english)
Atrial fibrillation (AF) is the most frequent arrhythmia in the general population today. It occurs at any age, but its incidence is growing in the older population. AF significantly affects mortality and quality of life. AF treatment includes rhythm and rate control as well as the prevention of thromboembolic events and stroke risk. Stroke implies the sudden loss of focal neurological functions due to a disturbance of cerebral blood flow that are mainly a consequence of ischemia, and if the outbreaks are shorter than one hour, we call them transient ischemic attacks (TIAs). It is considered that the AF increases the risk for stroke approximately five times, and when such a stroke occurs, it has more serious consequences and heavier handicaps compared to the other stroke etiologies. For the assesment of stroke risk in patients with AF we use scoring of the risk factor burden with CHADS2 and CHA2DS2-VASc calculations. Specific antithrombotic therapy is prescribed according to the result obtained. For the patients at risk antiplatelet (aspirin) or anticoagulant therapy with warfarin or, recently, new oral anti-coagulants (NOACs), which have equal or superior clinical efficacy and less side effects, should be initiated.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:105:571700
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2017-11-28 12:39:08